Schizophrenia — Animal Models & Behavioral Testing

No single model captures all symptom domains of schizophrenia. MK-801 is best for rapid antipsychotic screening targeting positive symptoms (hyperlocomotion, PPI deficits). Chronic PCP produces sustained negative and cognitive symptoms for testing novel pro-cognitive and pro-social compounds. Poly(I:C) MIA captures the neurodevelopmental trajectory with all three symptom domains. DISC1 provides a genetic model with dissociable positive (L100P) and negative (Q31L) symptom variants. Most preclinical programs use at least two models to cover multiple symptom domains.

PPI is the normal attenuation of a startle reflex when a weak stimulus (prepulse) precedes a strong startling stimulus by 30–500 ms. PPI is consistently impaired in schizophrenia patients and is disrupted by NMDA antagonists (MK-801, PCP) and dopamine agonists in mice. PPI rescue by antipsychotics has strong predictive validity — drugs that restore PPI in animal models tend to reduce positive symptoms in patients. PPI is measured in an acoustic startle chamber and provides one of the most translational biomarkers in psychiatric research.

Both are NMDA receptor antagonists, but their protocols and behavioral profiles differ. MK-801 is typically given acutely (single injection) producing transient hyperlocomotion and PPI deficits lasting 2–4 hours — ideal for rapid positive symptom screening. Chronic PCP (twice daily for 5–7 days followed by washout) produces persistent negative symptoms (social withdrawal) and cognitive deficits (working memory, recognition memory) lasting 1–2 weeks. Chronic PCP better models the treatment-resistant negative and cognitive domains that are the primary unmet clinical need.

Poly(I:C) injection to pregnant dams at E9 or E12.5 activates TLR3 signaling, triggering maternal IL-6 and type I interferon release. These cytokines disrupt fetal brain development, particularly GABAergic interneuron migration and prefrontal cortical lamination. Offspring appear normal during juvenile development but develop behavioral deficits in adulthood — mimicking the prodromal-to-onset trajectory of human schizophrenia. The timing of maternal immune activation determines symptom specificity: E9 injection biases toward positive symptoms, while E12.5 produces a broader phenotype.

DISC1 (Disrupted-in-Schizophrenia 1) was identified at the breakpoint of a chromosomal translocation that cosegregated with schizophrenia, major depression, and bipolar disorder in a large Scottish family. The DISC1 protein interacts with PDE4B (cAMP signaling), NDE1/NDEL1 (neuronal migration), and GSK3-beta (Wnt signaling). Mouse models with DISC1 point mutations show dissociable phenotypes: L100P mutants model positive symptoms with hyperlocomotion and PPI deficits, while Q31L mutants model negative symptoms with social withdrawal and depressive-like behavior.

Yes, and this is a major application. The MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) initiative identified working memory, attention, and executive function as priority cognitive targets. Chronic PCP and MIA models produce persistent cognitive deficits testable via Y-Maze (working memory), novel object recognition (declarative-like memory), and attentional set-shifting (executive function). Compounds that improve these endpoints in post-PCP-washout animals have the best translational track record for cognitive enhancement in schizophrenia.

A minimum battery for schizophrenia models includes: (1) Acoustic startle chamber for PPI — the primary translational biomarker; (2) Open field for locomotor hyperactivity and amphetamine sensitization; (3) Social interaction apparatus for negative symptom assessment; and (4) Y-Maze or novel object recognition for cognitive deficit testing. Adding fear conditioning for latent inhibition and forced swim for motivational deficits provides comprehensive coverage of positive, negative, and cognitive symptom domains.

Validation depends on the symptom domain. For positive symptoms: the drug should reverse MK-801-induced hyperlocomotion in the open field and restore PPI in the acoustic startle chamber. For negative symptoms: the drug should increase social interaction time in chronic PCP-treated or DISC1 Q31L mice without simply increasing general locomotion. For cognitive symptoms: the drug should improve Y-Maze alternation or NOR discrimination index in chronic PCP-washout animals. Always include a motor function control (rotarod or open field locomotion) to rule out non-specific sedation.